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e005033.Body Mass Index, Central Obesity,
and Mortality Among
Coronary Disease Subjects
In their recent study, Coutinho et al. (1) concluded that normal
body mass index with central obesity was associated with the
highest risk of mortality in subjects with coronary artery disease.
However, there is an uncertainty in interpreting the results of
this study.
It is well known that medication use such as chronic statin
therapy is closely associated with overall mortality in subjects
with coronary artery disease or other cardiovascular diseases such
as stroke and that subjects with obesity are more likely to be
treated by use of medication such as chronic statin therapy
because of metabolic abnormalities. In the study by Coutinho
et al. (1), however, medication use such as chronic statin therapy
was not described in detail, and the development of parsimo-
nious Cox model was not adjusted for medication use such as
chronic statin therapy. That is to say, medication use such as
chronic statin therapy was not discussed in detail, which could
have confounded the relationship of obesity to mortality in
subjects with coronary artery disease. In addition, many other
factors, which are well known to confound the relationship of
obesity to mortality in subjects with coronary artery disease or
other cardiovascular diseases such as strokedfor example,
including but not limited to the history of change of weight, the
condition of diet, weight loss, psychosocial stress, socioeconomicstatus, and physical activitydwere not described in detail in the
study by Coutinho et al. (1). Therefore it is unclear whether
normal body mass index with central obesity is associated with
the highest risk of mortality in subjects with coronary artery
disease when the above-mentioned factors, which might
confound the relationship of obesity to mortality, are taken into
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Cardiol 2013;61:553–60.ReplyWe thank Profs. Song, Wang, and Zhang for their interest in our
study (1).
Because our study was a meta-analysis with individual patient
data, information on statins was not uniformly available in all
studies included, and for this reason the use of statins was not
originally included in the models as a potential confounder.
Multivariable Cox proportional hazard models in the 6,313 of
the 15,547 participants with data on statin use and including
statin use as covariate showed that normal-weight central obesity
still had the highest mortality among all participants (analyses
not shown). Furthermore, in the setting of secondary prevention,
the relative risk reduction attributed to statins is approximately
20% (2), representing an association of lesser magnitude than the
increased risk found with normal-weight central obesity. Thus, it
is unlikely that the results of our study were driven by differences
in statin use among subjects with different body adiposity
patterns.
We recognize that there might be some residual confounding
attributed to differences among groups in weight change over time,
diet, psychosocial stress, socioeconomic status, and physical activity.
Unfortunately, we had limited information on these factors to
completely adjust in the multivariate models. However, we are not
aware of any evidence suggesting that subjects with normal-weight
central obesity would be more stressed, poorer, less likely to lose
weight, or have worse nutrition than people with general obesity or
other patterns of fat distribution, to suspect that these variables
would explain all of the association between normal-weight central
obesity and higher mortality.Thais Coutinho, MD
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Regarding Early Repolarization
PatternWe read with much interest the paper published by Wu et al. (1).
The paper summarized previous papers dealing with early repo-
larization pattern (ERP). In their meta-analysis, epidemiological
studies regarding ERP were selected to examine whether ERP was
associated with cardiac mortality in the general population.
Although they selected suitable studies, several questions arise in
their data analyses and interpretations.
First, we are concerned that the authors overestimated the results
of “death from cardiac cause” in their meta-analysis. We have care-
fully reviewed the risk ratios and corresponding person-years and
events of each study in Figure 2 of their paper (1).Although it is noted
that “total” represents person-years in the annotation, the numbers in
the “total” columndid not present the values of person-years in “death
from cardiac cause.” Indeed, the numbers in this “total” column
correspond exactly to the numbers of subjects with ERP or subjects
without ERP in each study cited. Because of these errors, the risk
ratios that the authors calculated were much lower than hazard ratios
reported in some studies. For example, the risk ratio for “death from
cardiac cause” is unrealistically low comparedwith that in the study of
Haruta et al. (2). We were concerned that the procedure used to
analyze “death from cardiac cause” was apparently different from
those used for “death from all causes” and “death from arrhythmia.”
Second, we are concerned about the different clinical outcomes
used to analyze “death from arrhythmia.” Haruta et al. (2) studied
an association between ERP and “unexplained death,” and Olson
et al. (3) set sudden cardiac death as an endpoint. In these studies,
whether or not arrhythmic death occurred was not clariﬁed.
Therefore, including the results of these two studies in the part of
“death from arrhythmia” may cause overestimation of the risk ratios
for arrhythmic death.
Third, the deﬁnition ofERPwas not consistent among the studies.
ERPwas identiﬁed when J-point elevation was present in at least two
leads in most studies, whereas J-point elevation in any lead was used
to identify ERP in the study by Olson et al. (3). Thus, comparing the
risk ratios of these studies does not yield an accurate conclusion. Inaddition, Haruta et al. (2) included Brugada-type electrocardio-
graphic ﬁndings in ERP, which may increase the incidence of
unexplained death. Therefore, caution is required in interpreting
ERP as a potential phenotype as is stated by Wu et al. (1).*Hideki Hayashi, MD, PhD
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3098–106.ReplyWe read the letter fromDr. Hayashi and colleagues and checked our
data carefully (1). We found an error in the “total” columns. The
“total” columns in our paper are subjects with and without ERP, not
person-years. However, the overall estimated effect did not change
when we re-estimated the overall effect for “death from cardiac
cause” using person-years instead of subjects. According to our re-
estimated effect, we also did not overestimate the results of “death
from cardiac cause” in our meta-analysis. We are sorry for the error.
We did not overestimate the risk ratios for arrhythmic death.
The study population in the paper by Olson et al. (2) came from the
ARIC (Atherosclerosis Risk in Communities) study, and sudden
cardiac death means arrhythmia-related death Unexplained death in
the paper by Haruta et al. (3) included unexplained accidental death
and sudden death, generally meaning arrhythmia-related death.
Early repolarization pattern (ERP) was characterized by an
elevation 0.1 mV of the QRS-ST junction (J point) in the inferior
and/or lateral leads on 12-lead electrocardiography. Also, we limited
ERP to either QRS notching or slurring in our meta-analysis, which
was different from the QRS morphology of Brugada syndrome. So,
we did not overestimate the risk ratios for arrhythmic death owing to
including some patients with Brugada syndrome.*Su-Hua Wu, MD, PhD
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